CCR5 antagonist 1 is primarily used in the field of medical research and therapy, particularly in the treatment of HIV/AIDS. It works by blocking the CCR5 receptor on the surface of immune cells, which is a key entry point for the HIV virus. By inhibiting this receptor, the antagonist prevents the virus from entering and infecting healthy cells, thereby slowing the progression of the disease. This makes it a valuable component in antiretroviral therapy regimens. Additionally, CCR5 antagonist 1 is being studied for its potential applications in other conditions where the CCR5 receptor plays a role, such as inflammatory diseases and certain cancers. Its ability to modulate immune responses also opens avenues for research in autoimmune disorders and organ transplantation.